Peking University Cancer Hospital & Institute

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

186

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

17 drugs in development

Phase 33

Phase 27

Phase 17

Preclinical3

By Therapeutic Area

top 2

Oncology

1571%

Cardiovascular

15%

R&D Momentum

82/100

Pipeline Velocity

54/100

Trial Completion Rate

90/100

Pipeline Concentration

57/100

Pipeline Freshness

56/100

Strategic Signals

↗Active in Cardiovascular but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Nov 4, 2026

Terminated

A Phase II Multi-cohort Clinical Study Evaluating The Efficacy and Safety of KN046 in Combination With Regorafenib for Metastatic Microsatellite-Stable Colorectal Cancer: a Phase II Multi-cohort Study

Nov 3, 2026

Recruiting

A Single-Arm Clinical Trial of QL1706 Combined With Celecoxib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Prior ICI Therapy

Oct 28, 2026

Recruiting

An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Earlier

Oct 21, 2026TrialEffectiveness and Safety of Stereotactic Body Radiotherapy Combined With Iparomlimab and Tuvonralimab and Bevacizumab in Patients With Locally Advanced or Oligometastatic Hepatocellular Carcinoma: A Prospective, Single-Arm, Single-Center Study

Oct 17, 2026TrialA Phase II Clinical Study Evaluating The Efficacy and Safety of KN046 in Combination With Regorafenib or Apatinib for Microsatellite Instability-High Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Oct 3, 2026TrialEfficacy and Safety of Iparomlimab and Tuvonralimab Injection(Anti-PD-1/CTLA-4 Bispecific Antibody) Combined With Recombinant Human GM-CSF Oncolytic HSV-2 (OH2) Injection (Vero Cells) for Perioperative Treatment of Stage III Resectable Acral Melanoma: A Prospective, Randomized, Controlled, Multicenter Clinical Study

Oct 2, 2026TrialTrastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase II, Multicenter, Single-Arm Study

Oct 2, 2026TrialA Single-arm, Multicenter, Phase II Study of RC48 Plus Platinum With or Without Bevacizumab in the Treatment of HER-2 Expression Platinum-Sensitive Recurrent Ovarian Cancer

3 more events

Oct 2, 2026TrialChemotherapy Combined With Bevacizumab Followed by Niraparib Monotherapy in Newly Diagnostic Advanced Ovarian Cancer With HRD Positive : A Perspective, Multicenter, Single-arm Phase II Trial

Oct 1, 2026TrialConstruction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe

Sep 30, 2026TrialClinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes

Details